Advertisement
Australia markets close in 1 hour 17 minutes

  • ALL ORDS

    7,906.20
    +45.20 (+0.57%)
     

  • ASX 200

    7,650.80
    +45.20 (+0.59%)
     

  • AUD/USD

    0.6448
    +0.0012 (+0.18%)
     

  • OIL

    82.79
    +0.10 (+0.12%)
     

  • GOLD

    2,389.50
    +1.10 (+0.05%)
     

  • Bitcoin AUD

    95,652.09
    -3,957.23 (-3.97%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • AUD/EUR

    0.6037
    +0.0011 (+0.19%)
     

  • AUD/NZD

    1.0890
    +0.0017 (+0.15%)
     

  • NZX 50

    11,809.17
    -66.18 (-0.56%)
     

  • NASDAQ

    17,493.62
    -220.04 (-1.24%)
     

  • FTSE

    7,847.99
    +27.63 (+0.35%)
     

  • Dow Jones

    37,753.31
    -45.66 (-0.12%)
     

  • DAX

    17,770.02
    +3.79 (+0.02%)
     

  • Hang Seng

    16,469.29
    +217.45 (+1.34%)
     

  • NIKKEI 225

    38,130.04
    +168.24 (+0.44%)
     

Aziyo Biologics to Report Second Quarter 2021 Financial Results on Monday, August 9, 2021

Aziyo Biologics
·1-min read

SILVER SPRING, Md., July 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its second quarter earnings results after market close on Monday, August 9, 2021. Management will host a conference call to review the company’s financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the Aziyo website at www.aziyo.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (833) 665-0667 (US/Canada) or (914) 987-7319 (International) and use the conference ID number 9977823 approximately ten minutes prior to the start time.

About Aziyo Biologics
Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit www.Aziyo.com.

Investors:
Leigh Salvo
Gilmartin Group
investors@aziyo.com

Media:
Courtney Guyer
Aziyo Biologics, Inc.
PR@aziyo.com